Abiopharma

🔍 Chang Chien Shen (Director)

Company: ASE Technology Holding Co., Ltd. (ASX)

Report Date: 2026-04-09

Detailed Transactions and Holdings:

• Acquired 3,000,000 shares of Ordinary Shares at $41.1 per share (Direct)
  Date: 2026-04-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,747,647.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,500,000 shares of Ordinary Shares at $99.7 per share (Direct)
  Date: 2026-04-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,247,647.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-04-09 | Code: H | nature_of_ownership: By ASE Enterprises Limited | shares_owned_after: 684,327,886.00
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-04-09 | Code: H | nature_of_ownership: By Value Tower Ltd. | shares_owned_after: 265,024,820.00
• Sold 3,000,000 shares of Stock Option (Right to Buy) at $41.1 per share (Derivative)
  Date: 2026-04-09 | Code: M | Expires: 2028-11-22 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,500,000 shares of Stock Option (Right to Buy) at $99.7 per share (Derivative)
  Date: 2026-04-09 | Code: M | Expires: 2033-08-17 | equity_swap_involved: 0 | shares_owned_after: 1,500,000.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: New Taiwan Dollars.
• F2: Reflects stock options to purchase Ordinary Shares. These stock options were granted on November 23, 2018 and are fully vested and exercisable.
• F3: Reflects stock options to purchase Ordinary Shares. These stock options were granted on August 18, 2023 and vest in seven semi-annual installments. 40% of the options vested on August 18, 2025, 10% of the options vested on February 18, 2026, and the remaining installments will vest at10% each on August 18 2026, February 18, 2027, August 18, 2027, February 18, 2028 and August 18, 2028.